Last reviewed · How we verify
NCT05569655
Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH
NA trial testing Tolvaptan in Pulmonary Arterial Hypertension in 100 participants. Status unknown.
30 November 2022
Quick facts
| Lead sponsor | Chinese Pulmonary Vascular Disease Research Group |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 6 April 2021 |
| Primary completion | 30 November 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tolvaptan (TOLVAPTAN) — full drug profile →
- Furosemide (furosemide) — full drug profile →
Conditions studied
- Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →
- Randomized Controlled Trial — all drugs for Randomized Controlled Trial →
Sponsor
Chinese Pulmonary Vascular Disease Research Group
Who can join
18 and older, any sex, with Pulmonary Arterial Hypertension or Randomized Controlled Trial. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Efficacy and safety evaluation of tolvaptan in the treatment of patients with right heart failure caused by pulmonary arterial hypertension
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05569655
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tolvaptan
Trials testing the same drug.
- NCT06506994 — A Study of HRS-9057 in Patients With Heart Failure and Volume Overload · Phase 1 · completed
- NCT06171100 — Low-dose Tolvaptan for Inpatient Hyponatraemia. · unknown
- NCT03949894 — Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domI · Phase 4 · completed
- NCT03764605 — Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease · Phase 3 · unknown
- NCT03541447 — Tolvaptan-Octreotide LAR Combination in ADPKD · Phase 2 · completed
Other recruiting trials for Pulmonary Arterial Hypertension
Currently open trials in the same condition.
- NCT07391228 — Cognitive Alterations in Pulmonary Arterial Hypertension (PAH) · active not recruiting
- NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
- NCT07217522 — Rutgers University Study of the Genetics of Pulmonary Hypertension · recruiting
- NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
- NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting
Other Chinese Pulmonary Vascular Disease Research Group trials
Trials by the same sponsor.
- NCT07481877 — Portosystemic Shunt-associated Pulmonary Hypertension Multi-center Prospective Cohort Study · not yet recruiting
- NCT05566002 — Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension · recruiting
- NCT05553015 — A Real-World Registry Investigating TReprostInil sodiUM in Pulmonary Hypertension (Re-TRIUMPH) · unknown
- NCT05595200 — Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension · unknown
- NCT06135909 — CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05569655 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Pulmonary Vascular Disease Research Group
- Last refreshed: 6 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05569655.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing